BUSINESS AREA

Labtech

Companies in the Labtech business area are active in the market areas diagnostics, biomedical research and laboratory equipment.

Labtech's net sales increased by 15 percent in the first quarter to SEK 989m (863). The organic sales growth amounted to 12 percent and the acquired growth amounted to 3 percent. Exchange rate changes had a marginally negative impact on net sales. EBITA increased by 21 percent to SEK 120m (99), corresponding to an EBITA margin of 12.1 percent (11.5). 

The development in Labtech was positive during the quarter, with growth across all segments and geographies. Instrument sales were higher compared to the relatively low volume in the first quarter of 2024. Margins strengthened during the quarter thanks to higher volumes but also due to ongoing improvement and efficiency efforts within several companies, which are now yielding concrete results.

The diagnostics business is stable and growing, while some caution and uncertainty still exist regarding investments, particularly in academic research. Demand from customers in the pharmaceutical industry remains strong.

Results from tenders won in previous quarters have started to show, and important new tenders have also been won during the first quarter.

The companies within AddLife provide market-leading service, which creates strong customer and supplier relationships and differentiation as other players cut back on service resources.

Active work is underway to develop product portfolios and bring in new suppliers of advanced products within prioritized segments, and progress is being made.